Searched for: in-biosketch:true
person:nowaka01
Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent
Mack, Douglas P; Dribin, Timothy E; Turner, Paul J; Wasserman, Richard L; Hanna, Mariam A; Shaker, Marcus; Tang, Mimi L K; RodrÃguez Del RÃo, Pablo; Sobolewski, Brad; Abrams, Elissa M; Anagnostou, Aikaterini; Arasi, Stefania; Bajowala, Sakina; Bégin, Philippe; Cameron, Scott B; Chan, Edmond S; Chinthrajah, Sharon; Clark, Andrew T; Detjen, Paul; du Toit, George; Ebisawa, Motohiro; Elizur, Arnon; Factor, Jeffrey M; Greiwe, Justin; O'B Hourihane, Jonathan; Hughes, Sarah W; Jones, Douglas H; Muraro, Antonella; Nowak-Wegrzyn, Anna; Patel, Nandinee B; Scurlock, Amy M; Shah, Atul N; Sindher, Sayantani B; Tilles, Stephen; Vickery, Brian P; Wang, Julie; Windom, Hugh H; Greenhawt, Matthew
BACKGROUND:Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included in the preparatory or consent process. OBJECTIVE:We developed consensus recommendations about the OIT process considerations and patient-specific factors that should be addressed before initiating OIT and developed a consensus OIT consent process and information form. METHODS:We convened a 36-member Preparing Patients for Oral Immunotherapy (PPOINT) panel of allergy experts to develop a consensus OIT patient preparation, informed consent process, and framework form. Consensus for themes and statements was reached using Delphi methodology, and the consent information form was developed. RESULTS:The expert panel reached consensus for 4 themes and 103 statements specific to OIT preparatory procedures, of which 76 statements reached consensus for inclusion specific to the following themes: general considerations for counseling patients about OIT; patient- and family-specific factors that should be addressed before initiating OIT and during OIT; indications for initiating OIT; and potential contraindications and precautions for OIT. The panel reached consensus on 9 OIT consent form themes: benefits, risks, outcomes, alternatives, risk mitigation, difficulties/challenges, discontinuation, office policies, and long-term management. From these themes, 219 statements were proposed, of which 189 reached consensus, and 71 were included on the consent information form. CONCLUSION/CONCLUSIONS:We developed consensus recommendations to prepare and counsel patients for safe and effective OIT in clinical practice with evidence-based risk mitigation. Adoption of these recommendations may help standardize clinical care and improve patient outcomes and quality of life.
PMID: 38597862
ISSN: 1097-6825
CID: 5657312
College-bound with allergies: When the days are long and the years are short [Editorial]
Shaker, Marcus S; Nowak-Wegrzyn, Anna
PMID: 38702098
ISSN: 1534-4436
CID: 5734322
Current and future perspectives on the consensus guideline for food protein-induced enterocolitis syndrome (FPIES)
Anvari, Sara; Ruffner, Melanie A; Nowak-Wegrzyn, Anna
Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE mediated food allergy presenting with delayed onset of projectile vomiting in the absence of cutaneous and respiratory symptoms. The pathophysiology of FPIES remains poorly characterized. The first international consensus guidelines for FPIES were published in 2017 and provided clinicians with parameters on the diagnosis and treatment of FPIES. The guidelines have served as a resource in the recognition and management of FPIES, contributing to an increased awareness of FPIES. Since then, new evidence has emerged, shedding light on adult-onset FPIES, the different phenotypes of FPIES, the recognition of new food triggers, center-specific food challenge protocols and management of acute FPIES. Emerging evidence indicates that FPIES impacts both pediatric and adult population. As a result, there is growing need to tailor the consensus guidelines to capture diagnoses in both patient groups. Furthermore, it is crucial to provide food challenge protocols that meet the needs of both pediatric and adult FPIES patients, as well as the subset of patients with atypical FPIES. This review highlights the evolving clinical evidence relating to FPIES diagnosis and management published since the 2017 International FPIES Guidelines. We will focus on areas where recent published evidence may support evolution or revision of the guidelines.
PMID: 38326194
ISSN: 1440-1592
CID: 5632282
The Future of Food Allergy Management: Advancements in Therapies
Ezhuthachan, Idil D; Beaudoin, Michele; Nowak-Wegrzyn, Anna; Vickery, Brian P
PURPOSE OF REVIEW/OBJECTIVE:To review current and future treatment options for IgE-mediated food allergy. RECENT FINDINGS/RESULTS:Recent years have seen major developments in both allergen-specific and allergen-non-specific treatment options, with the first FDA-approved peanut oral immunotherapy (OIT) product becoming available in 2020. In addition to OIT, other immunotherapy modalities, biologics, adjunct therapies, and novel therapeutics are under investigation. Food allergy is a potentially life-threatening condition associated with a significant psychosocial impact. Numerous products and protocols are under investigation, with most studies focusing on OIT. A high rate of adverse events, need for frequent office visits, and cost remain challenges with OIT. Further work is needed to unify outcome measures, develop treatment protocols that minimize adverse events, establish demographic and clinical factors that influence candidate selection, and identify patient priorities.
PMID: 38393624
ISSN: 1534-6315
CID: 5634552
Annals 80th anniversary: Immunotherapy for food allergy [Editorial]
Trogen, Brit; Nowak-Wegrzyn, Anna
PMID: 38569750
ISSN: 1534-4436
CID: 5694682
Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force
RodrÃguez Del RÃo, Pablo; Ãlvaro-Lozano, Montserrat; Arasi, Stefania; Bazire, Raphaëlle; Escudero, Carmelo; Patel, Nandinee; Sandoval-Ruballos, Monica; Vazquez-Ortiz, Marta; Nowak-Wegrzyn, Anna; Blümchen, Katharina; Dunn Galvin, Audrey; Deschildre, Antoine; Greenhawt, Matthew; Schnadt, Sabine; Riggioni, Carmen; Remington, Benjamin C; Turner, Paul; Fernandez Rivas, Montserrat
Food allergy is a global public health problem that until recent years lacked any aetiological treatment supported by academy, industry and regulators. Food immunotherapy (AIT) is an evolving treatment option, supported by clinical practice and industry trial data. Recent AIT meta-analyses have highlighted the difficulty in pooling safety and efficacy data from AIT trials, due to secondary heterogeneity in the study. An EAACI task force (CO-FAITH) initiated by the Paediatric Section was created to focus on AIT efficacy outcomes for milk, egg and peanut allergy rather than in trial results. A systematic search and a narrative review of AIT controlled clinical trials and large case series was conducted. A total of 63 manuscripts met inclusion criteria, corresponding to 23, 21 and 22 studies of milk, egg and peanut AIT, respectively. The most common AIT efficacy outcome was desensitization, mostly defined as tolerating a maintenance phase dose, or reaching a particular dose upon successful exit oral food challenge (OFC). However, a large degree of heterogeneity was identified regarding the dose quantity defining this outcome. Sustained unresponsiveness and patient-reported outcomes (e.g. quality of life) were explored less frequently, and to date have been most rigorously described for peanut AIT versus other allergens. Change in allergen threshold assessed by OFC remains the most common efficacy measure, but OFC methods suffer from heterogeneity and methodological disparity. This review has identified multiple heterogeneous outcomes related to measuring the efficacy of AIT. Efforts to better standardize and harmonize which outcomes, and how to measure them must be carried out to help in the clinical development of safe and efficacious food allergy treatments.
PMID: 38263695
ISSN: 1398-9995
CID: 5624922
Food allergy ladders: when to use them?
Meyer, Rosan; Nowak-Wegrzyn, Anna
PMID: 38056525
ISSN: 1534-4436
CID: 5595792
Allergic reactions during travel among individuals with IgE-mediated food allergy
Brady, Kathryn; Martinez-Flores, Beatriz; Trogen, Brit; Cruz-Vasquez, Joseline; Nowak-Wegrzyn, Anna
PMID: 37925073
ISSN: 2213-2201
CID: 5607202
Baked Milk and Egg Diets Revisited
Upton, Julia E M; Wong, Dennis; Nowak-Wegrzyn, Anna
Most milk and egg allergic children are non-reactive to modified forms of milk and egg in bakery products such as muffins due to conformational changes in proteins. These baked milk (BM) and baked egg (BE) diets have become commonplace in the management of milk and egg allergy, respectively. Current laboratory and skin test based diagnostic approaches remain limited in their ability to predict BM/BE tolerance, resulting in various approaches to introduce these foods. One approach to introduce BM/BE is to offer a medically supervised oral food challenge (OFC) and then advise dietary introduction of baked products for children who are tolerant. Another approach is adapted from a home-based protocol of graded ingestion of BM or BE originally intended for non-IgE mediated allergy, often referred to as a "ladder." The ladder advises home-ingestion of increasing amounts of BM or BE. For children who are allergic to BM or BE, the ladder is essentially oral immunotherapy (OIT), although not always labeled or recognized as such. Risk assessment and education of patients suitable for home-introduction is essential. A home approach that may be called a ladder can also be used to escalate diets after demonstrated tolerance of baked forms by introducing lesser cooked forms of milk or egg after tolerating BM or BE. A randomized controlled trial provided clear evidence that baked diets can hasten the resolution of IgE-mediated milk allergy. BM/BE foods have an emerging role in the treatment of non-IgE mediated allergy. There is tangential evidence for BM and BE diets in the prevention of IgE-mediated allergy.
PMID: 38151097
ISSN: 1534-4436
CID: 5623212
Experience transitioning post-food allergy clinical trial participants to daily ingestion of retail food equivalents
Baker, Mary Grace; Cox, Amanda; Kattan, Jacob D; Oriel, Roxanne C; Tsuang, Angela; Agyemang, Amanda; Nowak-Wegrzyn, Anna; Flom, Julie D; Schaible, Allison; Groetch, Marion; Wang, Julie; Sicherer, Scott H
PMID: 37972920
ISSN: 2213-2201
CID: 5610952